343
Participants
Start Date
March 11, 2009
Primary Completion Date
June 21, 2010
Study Completion Date
June 21, 2010
orvepitant
neurokinin-1 antagonist
Placebo
Placebo to match orvepitant 30 mg and 60 mg
GSK Investigational Site, Brooklyn
GSK Investigational Site, Emmaus
GSK Investigational Site, Philadelphia
GSK Investigational Site, Philadelphia
GSK Investigational Site, Rockville
GSK Investigational Site, Charlottesville
GSK Investigational Site, Columbia
GSK Investigational Site, Jacksonville
GSK Investigational Site, Winter Park
GSK Investigational Site, Orlando
GSK Investigational Site, Garfield Heights
GSK Investigational Site, Dayton
GSK Investigational Site, Milwaukee
GSK Investigational Site, Springfield
GSK Investigational Site, Saint Charles
GSK Investigational Site, Little Rock
GSK Investigational Site, Dallas
GSK Investigational Site, Austin
GSK Investigational Site, Denver
GSK Investigational Site, Phoenix
GSK Investigational Site, Orange
GSK Investigational Site, Portland
GSK Investigational Site, Salem
GSK Investigational Site, Norwich
GSK Investigational Site, Weymouth
GSK Investigational Site, Willingboro
GSK Investigational Site, San Antonio
GSK Investigational Site, Penticton
GSK Investigational Site, Miramichi
GSK Investigational Site, Sydney
GSK Investigational Site, Mississauga
GSK Investigational Site, Gatineau
Lead Sponsor
GlaxoSmithKline
INDUSTRY